Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cladribine Tablets as an Exit Therapy Strategy: Alternative to Continuing Treatment and Plain Treatment Discontinuation in Ageing Stable RMS Patients

NCT06887426 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.

NCT NCT06887426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cladribine Tablets as an Exit Therapy Strategy: Alternative to Continuing Treatment and Plain Treatment Discontinuation in Ageing Stable RMS Patients
Lead sponsor
University Hospital, Strasbourg, France
Phase
Observational
Overall status
Completed
Start date
October 17, 2025
Completion date
June 1, 2026
Enrollment
450 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis